DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.…
Industry Peers
BiotechnologyKey Statistics
About Bright Minds Biosciences (CNSX: DRUG)
›
Bright Minds Biosciences (CNSX: DRUG) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 26 employees.
The shares were at 28.92 CAD on 18 November 2026, down 61.4% over 52 weeks. Its 52-week range is 25.95 CAD to 170.00 CAD: the price is 83.0% below the high and 11.4% above the low.
Its market capitalisation is 285.27M CAD.
Bright Minds Biosciences reports return on equity of -14.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 307.76M CAD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 22 December 2026.